Cargando…

Allosteric modulation of the farnesoid X receptor by a small molecule

The bile acid activated transcription factor farnesoid X receptor (FXR) regulates numerous metabolic processes and is a rising target for the treatment of hepatic and metabolic disorders. FXR agonists have revealed efficacy in treating non-alcoholic steatohepatitis (NASH), diabetes and dyslipidemia....

Descripción completa

Detalles Bibliográficos
Autores principales:	Gabler, Matthias, Kramer, Jan, Schmidt, Jurema, Pollinger, Julius, Weber, Julia, Kaiser, Astrid, Löhr, Frank, Proschak, Ewgenij, Schubert-Zsilavecz, Manfred, Merk, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931576/ https://www.ncbi.nlm.nih.gov/pubmed/29717168 http://dx.doi.org/10.1038/s41598-018-25158-5

Ejemplares similares

NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
por: Schmidt, Jurema, et al.
Publicado: (2015)

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast
por: Schierle, Simone, et al.
Publicado: (2019)

A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice
por: Heitel, Pascal, et al.
Publicado: (2020)

Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro
por: Heitel, Pascal, et al.
Publicado: (2018)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Tertiary Alkylamines as Nucleophiles in Substitution Reactions at Heteroaromatic Halide During the Synthesis of the Highly Potent Pirinixic Acid Derivative 2-(4-Chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic Acid (YS-121)
por: Gabler, Matthias, et al.
Publicado: (2011)

Systematic Assessment of Fragment Identification for Multitarget Drug Design
por: Brunst, Steffen, et al.
Publicado: (2021)

Targeting the Alternative Vitamin E Metabolite Binding Site Enables Noncanonical PPARγ Modulation
por: Arifi, Silvia, et al.
Publicado: (2023)

Kernel learning for ligand-based virtual screening: discovery of a new PPARγ agonist
por: Rupp, Matthias, et al.
Publicado: (2010)

Zafirlukast Is a Dual Modulator of Human Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptor γ
por: Göbel, Tamara, et al.
Publicado: (2019)

In silico polypharmacology: retrospective recognition vs. rational design
por: Proschak, Ewgenij
Publicado: (2014)

Heterodimer formation with retinoic acid receptor RXRα modulates coactivator recruitment by peroxisome proliferator-activated receptor PPARγ
por: Kilu, Whitney, et al.
Publicado: (2021)

Development and in vitro Profiling of Dual FXR/LTA4H Modulators
por: Schierle, Simone, et al.
Publicado: (2021)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning
por: Merk, Daniel, et al.
Publicado: (2018)

Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning
por: Merk, Daniel, et al.
Publicado: (2018)

Scaffold Hopping from Amodiaquine to Novel Nurr1 Agonist Chemotypes via Microscale Analogue Libraries
por: Willems, Sabine, et al.
Publicado: (2022)

Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists
por: Helmstädter, Moritz, et al.
Publicado: (2022)

Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs
por: Hagenow, Jens, et al.
Publicado: (2020)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

A Diverse Benchmark Based on 3D Matched Molecular Pairs for Validating Scoring Functions
por: Kalinowsky, Lena, et al.
Publicado: (2018)

PocketPicker: analysis of ligand binding-sites with shape descriptors
por: Weisel, Martin, et al.
Publicado: (2007)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Letter to the Editor regarding “Comparison of phytochemical composition of Ginkgo biloba extracts using a combination of non-targeted and targeted analytical approaches”
por: Wurglics, Mario, et al.
Publicado: (2021)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

AKR1B7 Is Induced by the Farnesoid X Receptor and Metabolizes Bile Acids
por: Schmidt, Daniel R., et al.
Publicado: (2011)

SBE13, a newly identified inhibitor of inactive polo-like kinase 1
por: Keppner, Sarah, et al.
Publicado: (2010)

Multi-Target Approaches in Metabolic Syndrome
por: Lillich, Felix F., et al.
Publicado: (2021)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Front Cover: Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning (ChemistryOpen 1/2019)
por: Merk, Daniel, et al.
Publicado: (2018)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qqv8cbe93crt1esocmmisq12hk